Objective: To examine whether obesity/overweight is a risk predictor for breast cancer recurrence and death by menopausal status in a retrospective study. . The clinicopathological characteristics and clinical outcomes of patients within 5 years following breast cancer diagnosed were analyzed. Subgroup analyses of BMI on breast cancer prognosis were analyzed according to the menopausal status when breast cancer diagnosis. The Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).
Introduction
Nowadays, obesity or overweight has become an emerging health concern worldwide with over 500 million adults were obese and 958 million were overweight in 2008, [1, 2] and overweight or obesity was also reported to be a risk factor for increased incidence of various forms of cancer. [3, 4] Breast cancer remains the most common malignant neoplasm among women, [5] and being overweight or obese in adults is correlated with a greater risk of breast cancer. [6] Besides its established role as a risk factor, there is now widespread consensus on the importance of obesity or overweight as a negative prognostic factor for breast cancer. [7, 8] In 2004, Berclaz et al [9] have reported that obesity or overweight is associated with a poor prognosis after breast cancer treatment, and other studies also suggested that obesity at the time of cancer diagnosis or pre-diagnosis is associated with poor prognosis for breast cancer patients. [10, 11] In addition, it has been demonstrated that breast cancer patients with higher body mass index (BMI) estimated as obesity or overweight have a worse prognosis disease regardless of tumor subtype. [12] However, a large retrospective study including stage I-III triple-negative breast cancer (TNBC) patients found that overweight (BMI 25-29.9 kg/m 2 ) or obesity (BMI ≥ 30 kg/m 2 ) at diagnosis did not affect disease-free survival (DFS) or overall survival (OS), [13] and Kwan et al [14] also did not find any association between BMI and risk of breast cancer recurrence or mortality after nearly 8-year follow-up.
According to previous study, the effects of higher BMI on prognosis of breast cancer may be associated with menopausal status. [15] Berclaz et al [9] demonstrated that elevated BMI is significantly associated with a worse prognosis of breast cancer, especially for premenopausal and perimenopausal patients, and Kawai et al [16] found that higher BMI (BMI ≥25.8 kg/m 2 ) was associated with an increase in mortality for premenopausal patients. In a cohort study, obese postmenopausal women at diagnosis were at increased risk of breast cancer mortality compared to normal weight women after 6-year follow-up, while being overweight did not affect survival. [17] Another study found that both obesity and overweight were associated with a nonsignificant higher risk of recurrence and breast cancer death for premenopausal women, and obesity was associated with a significant higher risk of breast cancer death (not for recurrence), but overweight was not a prognosis predictor for postmenopausal women. [18] To date, the relationship between obesity/overweight and outcomes of breast cancer patients has not been well defined. To our knowledge, the association between obesity/overweight and risk of breast cancer recurrence and death in Chinese women according to menopausal status is less well understood mechanistically. In our study, we presented the analysis of the link between BMI and prognosis of breast cancer, and the stratification analysis was also conducted according to menopausal status when breast cancer diagnosis.
Methods

Patient selection
Data in the study were extracted from the hospital recording statistics in the Affiliated Changzhou No. 2. People's Hospital with Nanjing Medical University from January 2004 to December 2012. We collected primary and adjuvant treatment from medical records: surgery, radiation, chemotherapy, and specific hormonal therapy. We examined a number of potential confounding variables including age when breast cancer diagnosis, stage at diagnosis, tumor size, lymph node evaluation, estrogen receptor (ER) or progesterone receptor (PR) expression, human epidermal growth factor receptor-2 (HER2) expression, pathological subtype, and histological grade. Survival data, which included date of breast cancer diagnosis, surgery, relapse, death and last follow-up, were collected in this cohort. The diagnostic of breast cancer was based on the pathological diagnosis. Patients who did not perform surgery were excluded. We further excluded patients who were without complete medical records, dying from other Table 1 Comparison of clinicopathological characteristics among breast cancer patients according to the body mass index (kg/m 2 ). (192) . Furthermore, a stratified analysis about relationship between BMI and prognosis of breast cancer was conducted in line with menopausal status when breast cancer diagnosed. Menopausal status was defined by 1 year of amenorrhea, or previous bilateral oophorectomy. In the present study, a total of 416 breast cancer patients were postmenopausal, and 601 breast cancer patients were premenopausal. The differences in clinicopathologic characteristics and 5-year breast cancer outcomes between 3 groups were compared.
Follow-up and outcomes
Follow-up has been maintained by reviewing clinical charts and by contacting patients via telephone or mail. Events used for the Table 2 Univariate analysis of 5-year survival for all patients. BMI = body mass index, DFS = disease-free survival, ER = estrogen receptor, HER2 = human epidermal growth factor receptor-2, IDC = invasive ductal cancer, OS = overall survival, PR = progesterone receptor. analysis were 5-year mortality of breast cancer or relapse including local, regional and contralateral breast cancer or distant breast cancer recurrence. Survival status was censored at the date of last contact or 31 December 2017 (last follow-up). DFS defined as the time of diagnosis to development of first evidence of recurrence (distant metastasis or local regional recurrence) or date of last follow-up. OS was defined as from the time of diagnosis to last follow-up or time of mortality from breast cancer (patients dying from other causes within 5 years of breast cancer diagnosis were excluded).
Statistical analysis
In our study, the associations between different BMI groups and clinicopathologic characteristics of breast cancer patients were analyzed by the chi-square test. The Kaplan-Meier methods were used to calculate 5-year DFS and OS, and the significance was tested by log-rank test. Factors with P < .10 in univariate analysis were included in the multivariate Cox model for multivariate analysis. Multivariable Cox proportional hazard models were used to estimate the adjusted hazard ratios (HRs) of different BMI groups. In multivariate analysis, the normal weight group was regarded as a reference for calculating the HR of BMI. Stratified analyses were conducted to explore whether the effects of obesity or overweight on prognosis of breast cancer were modified by menopausal status. All statistical analyses were carried out with SPSS software (version 17.0), and P < .05 were considered statistically significant.
Results
Clinical characteristics of patients in study groups
The median follow-up time for this study was 80 months (13-140 months). Of the 1017 breast cancer patients, 474 were normal weight, 351 patients were overweight, and 192 were obesity. The clinicopathological features of these 3 groups were summarized in Table 1 . The older age (≥66 years) tended to distribute in overweight (14.0%) and obesity (16.1%) groups compared to normal weight group (6.8%) (P < .001). Besides, the larger size of tumors and postmenopausal patients were more likely to distribute (P < .001) in overweight and obesity groups, and less patients chose anthracycline and/or taxane to be chemotherapy regimen in these 2 groups (P = .036). Lymph node metastasis, pathological subtype, histological grade, ER and PR status, HER2 status, the percentages of patients receiving radiotherapy, and hormone therapy were not significantly different among these 3 groups (Table 1) .
5-Year DFS and OS
In total, 180 patients suffered from breast cancer relapse within 5 years after breast cancer diagnosis, and the number of recurrent patients was 60, 71, and 49 in the normal weight group, overweight group, and obesity group, respectively. The 5-year DFS and breast cancer relapse rate for the whole cohort were 82.3% (837/1017) and 17.7% (180/1017), respectively. A total of 115 patients died of breast cancer, 34 patients were in the normal weight group, 46 cases were in the overweight group, and 35 cases were in the obesity group. The 5-year OS and breast cancer mortality rate were 88.7% (902/1017) and 11.3% (115/ 1017), respectively. The Kaplan-Meier analysis showed that there was a significant difference in the DFS and OS between the three groups ( Table 2 ). The DFS was 87.3, 79.8, 74.5% for normal weight, overweight, and obesity groups, respectively (P < .001) ( Table 2 , Fig. 1a ). The OS was 92.8, 86.9, 81.8% for normal weight, overweight, and obesity groups, respectively (P < .001) ( Table 2 , Fig. 1B ). The 5-year DFS in the premenopausal and postmenopausal groups were 83.4% and 80.8% (P = .311) ( Table 2 ). The 5-year OS in the premenopausal and postmenopausal groups were 89.7% and 87.3% (P = .222) ( Table 2) . All factors were included in the univariate analysis, and the 5-year DFS and OS were significantly different in terms of lymph node status, tumor size, histological grade, expression of ER and PR, radiotherapy, and hormone therapy (P < .05) ( Table 2 ). In multivariate analysis, when compared with normal weight patients, the risks of 5-year breast cancer relapse (HR, 1.630; 95% confidence interval [CI], 1.150-2.311; P = .006) and mortality (HR, 1.747; 95% CI, 1.120-2.725; P = .014) for the overweight patients were significantly increased after adjusted for other variables, and the 5-year risks of breast cancer relapse (HR, 1.888; 95% CI, 1.281-2.783; P = .001) and mortality (HR, 2.052; 95% CI, 1.262-3.336; P = .004) were also significantly increased in obesity group after adjusting for age, lymph node status, tumor size, histological grade, ER, PR, radiotherapy, and hormone therapy (Table 3) .
BMI and prognosis of breast cancer for premenopausal patients
In univariate analysis, both the 5-year DFS and OS were significantly different among the 3 groups for premenopausal patients. The DFS was 86.7, 81.9, 75.5% for normal weight, overweight, and obesity groups, respectively (P = .026) ( Fig. 2A) , and the OS was 92.4, 88.3, 83.7% for normal weight, overweight, and obesity groups, respectively (P = .034) (Fig. 2B) (Table 4) . Besides, the 5-year DFS and OS were significantly different in terms of age, lymph node status, tumor size, histological grade, radiotherapy, and hormone therapy (Table 4) . By multivariate analysis, the 5-year risks of breast cancer relapse (HR, 1.824; 95% CI, 1.096-3.037; P = .021) and mortality (HR, 1.948; 95% CI, 1.029-3.687; P = .041) were Figure 2 . Kaplan-Meier analysis of 5-year survival outcomes for premenopausal breast cancer patients according to BMI. A, Disease-free survival. B, Overall survival. Statistically significant differences between the groups were estimated by log-rank test.
Table 4
Univariate analysis of 5-year survival for premenopausal patients (n = 601). (Table 5) .
BMI and prognosis of breast cancer for postmenopausal patients
When compared to the normal weight group, the 5-year DFS and OS of overweight and obesity groups for postmenopausal patients were significantly decreased. As shown in Table 6 , the 5-year DFS was 88.7, 77.3, 73.4% for normal weight, overweight, and obesity groups, respectively (P = .003) (Fig. 3A) ; the 5-year OS was 93.7, 85.3, 79.8% for normal weight, overweight, and obesity groups, respectively (P = .003) (Fig. 3B) . Additionally, the 5-year DFS and OS were significantly different in terms of lymph node status, tumor size, histological grade, PR expression, and hormone therapy (P < .05) ( Table 6) . By multivariate analysis, 5-year risks of relapse (HR, 1.884; 95% CI, 1.066-3.331; P = .029) and mortality (HR, 2.210; 95% CI, 1.040-4.696; P = .039) were increased for overweight group after adjusting for lymph node status, tumor size, histological grade, ER, PR, chemotherapy, and hormone therapy ( Table 7) .
The 5-year risks of breast cancer relapse (HR, 2.031; 95% CI, 1.091-3.782; P = .026) and mortality (HR, 2.493; 95% CI, 1.117-5.564; P = .026) were also increased in obesity group after adjusting confounding factors (Table 7) .
Discussion
Obesity and overweight in adults have been reported to be correlated with a greater risk of breast cancer, [6, 19] while the studies that evaluated influence of overweight and obesity on breast cancer survival have yielded mixed findings. [20, 21] In an effort to address this gap, we conducted a retrospective study to elucidate the relationship between obesity and breast cancer prognosis.
In our study, we found that overweight and obese breast cancer patients were associated with larger size tumors compared to normal weight patients. Additionally, patients tended to be older, the proportion of postmenopausal patients was increased, and lesser patients choose anthracycline and/or taxane to be chemotherapy regimen in overweight and obesity groups. There were also several studies demonstrating that obese women develop aggressive breast cancer with a significantly larger size compared to normal weight women, [22, 23] and patients with BMI ≥25 kg/m 2 tended to be older and to have larger tumor size, [24] postmenopausal patients were more distributed in patients with higher BMI (BMI≥25.8 kg/m 2 ). [16] Interestingly, some authors claimed that women with higher BMI undergo less screening so tend to have more advanced disease at presentation. [25] We also found that overweight and obesity were independent predictors for increased risks of 5-year breast cancer relapse and mortality for the whole cohort. In a previous study from America, after 5-year follow-up, the authors calculated that HRs for risks of recurrence was 1.18 (95% CI 1.02-1.36) in overweight patients and breast cancer mortality was 1.23 (95% CI 1.00-1.52) in the obese group relative to the normal weight, while overweight did not influence recurrence and obesity wasn't a predictor for breast cancer mortality. [20] In a study including African TNBC patients, overweight was significantly related to breast cancer mortality (HR 2.903, 95% CI: 1.551-5.432) and recurrence (HR 1.899, 95% CI: 1.05-3.433) by multivariable analysis. [26] Another study found that the risks of developing distant metastasis were significantly increased for Danish obese patients, while both obesity and overweight women had higher risk of breast cancer mortality relative to normal weight women. [27] However, Kawai et al [18] reported that obesity was an independent risk factor for breast cancer death (HR: 1.47; 95% CI: 1.11-1.93) but not for recurrence, and overweight had no association with breast cancer prognosis. Nevertheless, in another study from America, Kwan et al [14] observed that overweight or obesity was not associated with increased risk of Table 5 Multivariate Cox proportional hazards model for survival in premenopausal patients. BMI = body mass index, CI = confidence interval, DFS = disease-free survival, ER = estrogen receptor, HR = hazard ratio, NA = not applicable, OS = overall survival, PR = progesterone receptor.
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recurrence and breast cancer mortality compared to normal weight, a report from the Korean Breast Cancer Society demonstrated similar results. [21] Although the association between obesity/overweight and the prognosis of breast cancer patients remains controversial, it has been reported that impact of BMI on prognosis of breast cancer may relate to menopausal status. [15] To identify this issue, we conducted a stratified analysis according to the menopausal status.
In stratified analysis, we found that being overweight was associated with increased risks of breast cancer relapse and mortality within 5 years after breast cancer diagnosis for postmenopausal but not for premenopausal women, and obesity was an independently poor predictor for breast cancer relapse and mortality regardless to menopausal status. Similar to our study, Reeves et al [4] have reported that obesity and overweight were related to increased breast cancer progression and mortality primarily in British postmenopausal women. A meta-analysis of 82 studies that included 213,075 breast cancer patients demonstrated that obesity was associated with higher risk of breast cancer mortality (HR, 1.41; 95% CI, 1.29-1.53) in both premenopausal (HR, 1.75; 95% CI, 1.26-2.41) and postmenopausal (HR, 1.34; 95% CI, 1.18-1.53) women, [28] similar results were found by Niraula et al. [29] A study from Japan found that obesity and overweight were associated with a nonsignificant higher risk of recurrence and breast cancer death for premenopausal women, and obesity but not overweight was associated with a significant higher risk of breast cancer death for postmenopausal women (not for recurrence), [18] results from a cohort study also suggest that obesity (not overweight) was an independent poor prognostic predictor for American postmenopausal breast cancer patients. [17] However, some authors [9] found that overweight or obesity is significantly associated with a shorter OS and DFS for premenopausal and perimenopausal patients. Besides, another study including American breast cancer Table 6 Univariate analysis of 5-year survival for postmenopausal patients (n = 416). patients also stated that overweight or obesity was positively associated with recurrence in premenopausal rather than postmenopausal women. [15] Moreover, some studies indicated that overweight is an independent prognostic factor for increased breast cancer mortality and recurrence in premenopausal TNBC women, while similar results were not found in postmenopausal women. [26, 30] Although the effects of BMI on breast cancer prognosis are still controversial, the possible mechanisms have been disclosed as follow. Some authors reported that in postmenopausal patients with higher BMI, increased synthesis of peripheral estrogen in adipose tissue and reduced sex hormone binding globulin might be responsible for the poor breast cancer prognosis due to enhanced aromatase activity may induce and stimulate the growth of abnormal mammary cells, [31, 32] and higher BMI women may not fully benefit from aromatase inhibitors in postmenopausal women. [33] Furthermore, women with higher BMI and older age may withstand comorbidities and chemotherapy dose reduction due to concerns about toxicity, [34] and women with higher BMI may present increased levels of insulin, insulin-like growth factor, and hormones with potent mitogenic activity. [35] Besides, paracrine secretion of interleukin-6 and tumor necrosis factor-alpha and the establishment of a proinflammatory micro-environment may promote tumor growth, metastasis. [36] Several cytokines produced by obese adipose tissue may promote the progression of breast cancer via upregulating breast cancer stem cells, inhibiting the antitumor immunity and stimulating breast tumor angiogenesis. [37] Thus higher BMI might induce the development of breast cancer.
Our study found that obesity at diagnosis was related to poor prognosis of breast cancer irrespective of menopausal status, while overweight was only associated with prognosis of postmenopausal patients. However, our study has some limitations. Firstly, there is an active debate regarding the limitations of BMI to define obesity and overweight categories for various populations. [38] Secondly, negative effects of weight change on breast cancer prognosis have been reported, [39, 40] the association limited to BMI when cancer diagnosis may attenuate over time, but we did not dynamically monitor changes in body weight in breast cancer patients. Thirdly, obese patients are thought to have a higher risk of comorbid conditions, but our study did not include information on comorbidities. Finally, the sample size was small relatively, follow-up period was short, and we did not adjust other potential confounders. The limitations mentioned above may partly bring about the discrepancy in our study.
In conclusion, our study adds to the literature by showing a link of obesity, menopausal status, and breast cancer prognosis. However, further studies with larger sample sizes and more comprehensive design are urgently warranted. A/T = anthracycline and/or taxane, BMI = body mass index, CI = confidence interval, DFS = disease-free survival, ER = estrogen receptor, HR = hazard ratio, NA = not applicable, OS = overall survival, PR = progesterone receptor.
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